DE69533959D1 - Retrovirale vektoren, die von gegen lyse durch menschliches serum resistenten produktionszellinien produziert werden - Google Patents

Retrovirale vektoren, die von gegen lyse durch menschliches serum resistenten produktionszellinien produziert werden

Info

Publication number
DE69533959D1
DE69533959D1 DE69533959T DE69533959T DE69533959D1 DE 69533959 D1 DE69533959 D1 DE 69533959D1 DE 69533959 T DE69533959 T DE 69533959T DE 69533959 T DE69533959 T DE 69533959T DE 69533959 D1 DE69533959 D1 DE 69533959D1
Authority
DE
Germany
Prior art keywords
retroviral vectors
human serum
cellines
lyse
vectors produced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69533959T
Other languages
English (en)
Inventor
Michael Pensiero
Mary K L Collins
Francois-Loic Cosset
Yasuhiro Takeuchi
Robin A Weiss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Cancer Research
Genetic Therapy Inc
Original Assignee
Institute of Cancer Research
Genetic Therapy Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Cancer Research, Genetic Therapy Inc filed Critical Institute of Cancer Research
Application granted granted Critical
Publication of DE69533959D1 publication Critical patent/DE69533959D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
DE69533959T 1994-08-17 1995-08-17 Retrovirale vektoren, die von gegen lyse durch menschliches serum resistenten produktionszellinien produziert werden Expired - Lifetime DE69533959D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29176594A 1994-08-17 1994-08-17
US45121595A 1995-05-26 1995-05-26
PCT/US1995/010496 WO1996004934A1 (en) 1994-08-17 1995-08-17 Retroviral vectors produced by producer cell lines resistant to lysis by human serum

Publications (1)

Publication Number Publication Date
DE69533959D1 true DE69533959D1 (de) 2005-03-03

Family

ID=26966960

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69533959T Expired - Lifetime DE69533959D1 (de) 1994-08-17 1995-08-17 Retrovirale vektoren, die von gegen lyse durch menschliches serum resistenten produktionszellinien produziert werden

Country Status (7)

Country Link
US (2) US5952225A (de)
EP (1) EP0769968B1 (de)
JP (1) JPH10507905A (de)
AT (1) ATE287732T1 (de)
CA (1) CA2196208A1 (de)
DE (1) DE69533959D1 (de)
WO (1) WO1996004934A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69533959D1 (de) * 1994-08-17 2005-03-03 Genetic Therapy Inc Retrovirale vektoren, die von gegen lyse durch menschliches serum resistenten produktionszellinien produziert werden
US6818439B1 (en) * 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
US6117681A (en) * 1995-03-29 2000-09-12 Bavarian Nordic Research Inst. A/S Pseudotyped retroviral particles
CA2237000A1 (en) * 1995-11-08 1997-05-15 The Whitehead Institute For Biomedical Research Stable packaging cell line producing pseudotyped retroviruses
US5910434A (en) * 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
JP2000501614A (ja) * 1995-12-15 2000-02-15 システミックス，インコーポレイテッド 高形質導入効率を有するレトロウイルスベクター上清を得るための方法
WO1998000542A2 (en) * 1996-07-03 1998-01-08 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia
US20040019923A1 (en) * 1997-10-16 2004-01-29 Ivarie Robert D. Exogenous proteins expressed in avians and their eggs
EP1030928A1 (de) * 1997-11-21 2000-08-30 Gesellschaft für biotechnologische Forschung mbH (GBF) Ssdna oder dsdna, kodierte fusionsproteine, viren, verpackungszellinien und ihre verwendung
US6743631B1 (en) * 1998-03-17 2004-06-01 North Shore University Hospital Research Corporation Use of human serum resistant vector particles and cell lines for human gene therapy
GB0400443D0 (en) * 2004-01-09 2004-02-11 Oxford Biomedica Ltd Cascade
GB0122803D0 (en) * 2001-09-21 2001-11-14 Oxford Biomedica Ltd Vector
CA2371216A1 (en) * 1999-04-23 2000-11-02 Centre For Translational Research In Cancer Pseudotyped retroviral vector for gene therapy of cancer
AU2001240078A1 (en) * 2000-03-07 2001-09-17 St. Jude Children's Research Hospital Highly efficient gene transfer into human repopulating stem cells by rd114 pseudotyped retroviral vector particles
US6849454B2 (en) 2000-03-07 2005-02-01 St. Jude Children's Research Hospital Highly efficient gene transfer into human repopulating stem cells by RD114 pseudotyped retroviral vector particles
WO2002044394A2 (en) 2000-11-29 2002-06-06 University Of Southern California Targetet retoviral vectors for cancer immunotherapy
US20030113784A1 (en) * 2001-11-29 2003-06-19 Jaime Flores-Riveros Regulated expression of recombinant DNA
US7015035B2 (en) * 2002-11-05 2006-03-21 The Trustees Of Columbia University In The City Of New York RD114-based retroviral packaging cell line and related compositions and methods
US20070178066A1 (en) * 2003-04-21 2007-08-02 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
EP1795601B1 (de) * 2004-09-29 2014-01-22 Takara Bio Inc. Zelle zur produktion eines retrovirusvektors
US20060292159A1 (en) * 2005-06-08 2006-12-28 Ranscht Barbara E Methods for the inhibition of neovascularization and cancer metastasis
ES2703341T3 (es) 2013-03-14 2019-03-08 Genvivo Inc Ensayo diagnóstico de timidina quinasa para aplicaciones de terapia génica
WO2023131669A1 (en) * 2022-01-07 2023-07-13 Universite De Namur Methods for assessing resistance to non-integrating virus vectors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591624A (en) * 1988-03-21 1997-01-07 Chiron Viagene, Inc. Retroviral packaging cell lines
US5665577A (en) * 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
JPH06500923A (ja) * 1990-09-21 1994-01-27 カイロン　コーポレイション パッケージング細胞
US5470726A (en) * 1991-02-22 1995-11-28 Fred Hutchinson Cancer Research Center Retrovirus packaging and producer cell lines based on gibbon ape leukemia virus
EP0644946A4 (de) * 1992-06-10 1997-03-12 Us Health Gegen die inaktivierung durch menschliches serum resistente vektorpartikel.
CA2132194A1 (en) * 1993-01-19 1994-08-04 Robert R. Klevecz Method for control of chaotic systems
WO1994019478A1 (en) * 1993-02-22 1994-09-01 The Rockefeller University Production of high titer helper-free retroviruses by transient transfection
DE69533959D1 (de) * 1994-08-17 2005-03-03 Genetic Therapy Inc Retrovirale vektoren, die von gegen lyse durch menschliches serum resistenten produktionszellinien produziert werden

Also Published As

Publication number Publication date
US6329199B1 (en) 2001-12-11
WO1996004934A1 (en) 1996-02-22
US5952225A (en) 1999-09-14
EP0769968A4 (de) 1997-10-29
EP0769968A1 (de) 1997-05-02
EP0769968B1 (de) 2005-01-26
ATE287732T1 (de) 2005-02-15
JPH10507905A (ja) 1998-08-04
CA2196208A1 (en) 1996-02-22

Similar Documents

Publication Publication Date Title
DE69533959D1 (de) Retrovirale vektoren, die von gegen lyse durch menschliches serum resistenten produktionszellinien produziert werden
ATE237312T1 (de) In liposomen verkapselte nukleinsäurekomplexe
PT1053256E (pt) Anticorpos para o receptor de morte 4 (dr4) e utilizações destes
BG103664A (en) Pharmaceutical forms containing ammoxycillin and clavulanate
FI963103A (fi) Ei-virusvektori
ATE407362T1 (de) Screening von verbindungen zu ihrer fähigkeit um die herstellung von beta-amyloid peptiden zu veränderen
EP1361271A3 (de) Vom MAGE-3-Gen en abgeleitetes und von HLA-A1 präsentiertes, isoliertes Nonapeptid und dessen Anwendungen
EP2213302A3 (de) DR4-Antikörper und Verwendungen dafür
ATE193733T1 (de) Stahl für die herstellung von teilbaren maschinenteilen und maschinenteile, hergestellt aus diesen stahl
CA2278028A1 (en) Methods for improving transformation efficiency
EP0754229A1 (de) Afamin: ein menschliches serum albumin ähnliches protein
AU6682594A (en) Treatment of septic shock
MX9602557A (es) Proteinas de higado de mamifero y su uso en oncologia.
TR200000697T2 (tr) İkame edilmiş 1,2,3,4,5,6-Heksahidro-2,6-Metano-3-Benzazosin-10-OL'ler, üretim yöntemleri ve farmasötik preparat olarak kullanımları.
FR2742048B1 (fr) Utilisation de l'alpha-cyano-beta, beta-diphenylacrylate de 2-ethylhexyle pour ameliorer la stabilite de compositions cosmetiques contenant le p-methyl-benzylidene camphre en association avec un derive de dibenzoylmethane
MX9806041A (es) Proteina purificada sr-p70.
CA2047802A1 (en) Pharmaceutical compositions
CA2340934A1 (en) Novel collectin
CA2108358A1 (en) Gene expression in bacilli
HK1008225A1 (en) Somatostatin-analogous cyclic peptides with inhibitory activity on growth hormone
EP0868908A3 (de) Kosmetisches Mittel
CA2222718A1 (en) Attachment enhanced 293 cells
MX9803953A (es) Peptidos novedosos, preparacion y uso de los mismos.
EP0962533A3 (de) Auf Zucker reagierende Enhancer-Sequenzen aus alpha-Amylasegenen
DE69323191T2 (de) Wasserlösliche retinoide

Legal Events

Date Code Title Description
8332 No legal effect for de